This MedLibrary.org supplementary page on Zomig is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (November 2007) |
 |
|
 |
|
|
Zolmitriptan
|
|
| Systematic (IUPAC) name | |
| (4S)-4-{[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl}- 1,3-oxazolidin-2-one |
|
| Identifiers | |
| CAS number | |
| ATC code | N02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H21N3O2 |
| Mol. mass | 287.357 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 40% (oral) |
| Protein binding | 25% |
| Metabolism | ? |
| Half life | 3 hours |
| Excretion | Renal (65%) and fecal (35%) |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, nasal spray |
Zolmitriptan is an selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.
Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Greece & Argentina), AscoTop (Germany) and Zomigoro (France). In 2005, AstraZeneca generated $352 million in sales with Zomig.citation needed
Contents |
Description
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water.
Indications
Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Zolmitriptan comes in both a swallowable and oral disintegrating tablet. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame. [1]
Contraindications and precautions
Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.
Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.
Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.
Adverse reactions
The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient.
Serious cardiac events, including myocardial infarction, have been associated with zolmitriptan. These are, however, rare.
Reported minor adverse reactions include: hypesthesia, paresthesia (all types), warm and cold sensations, chest pain, throat and jaw tightness, dry mouth, dyspepsia, dysphagia, nausea, somnolence, vertigo, asthenia, myalgia, myasthenia and sweating.
References
- MacGregor, E.A. (1998). "Zolmitriptan clinical studies". Drugs Today 34 (12): 1027–1033. doi:.
- Newman, L.C & Lipton, R.B (2001). "Migraine MLT-Down: An Unusual Presentation of Migraine in Patients With Aspartame-Triggered Headaches" (abstract). Headache: The Journal of Head and Face Pain 41 (9): 899–901. doi:, http://www.blackwell-synergy.com/doi/abs/10.1046/j.1526-4610.2001.01164.x. Retrieved on 15 February 2008.
External links
- Zomig Information Site (USA)
- International Zomig Information for Health Care Professionals
- Full prescribing information from AstraZeneca
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 1 December 2008, at 03:40.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Zomig".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.